Literature DB >> 26067864

Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.

Amelia M Jernigan1, Haider Mahdi, Peter G Rose.   

Abstract

OBJECTIVES: To estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival. METHODS AND MATERIALS: A total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC- based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.
RESULTS: Of 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56-78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0-187.91) months. At a median survival of 5.97 (95% CI, 0.20-116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC- to HBOC+ women and did not reveal a significant difference for survival outcomes.
CONCLUSIONS: Confirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.

Entities:  

Mesh:

Year:  2015        PMID: 26067864     DOI: 10.1097/IGC.0000000000000489

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.

Authors:  Marina Stasenko; Paulina Cybulska; Noah Feit; Vicky Makker; Jason Konner; Roisin E O'Cearbhaill; Kaled M Alektiar; Kathryn Beal; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Dennis S Chi; Oliver Zivanovic; Mario M Leitao; Karen A Cadoo; William P Tew
Journal:  Gynecol Oncol       Date:  2019-05-18       Impact factor: 5.482

2.  Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report.

Authors:  Laure Favier; Gille Truc; Romain Boidot; Leïla Bengrine-Lefevre
Journal:  Mol Clin Oncol       Date:  2020-04-27

3.  Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.

Authors:  Alexandre André Balieiro Anastácio da Costa; Elizabeth Santana Dos Santos; Deborah Porto Cotrim; Natasha Carvalho Pandolfi; Marcelle Goldner Cesca; Henrique Mantoan; Solange Moraes Sanches; Adriana Regina Gonçalves Ribeiro; Louise de Brot; Graziele Bonvolim; Paulo Issamu Sanematsu; Ronaldo Pereira de Souza; Joyce Maria Lisboa Maya; Fabrício de Souza Castro; João Paulo da Nogueira Silveira Lima; Michael Jenwel Chen; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi
Journal:  BMC Cancer       Date:  2019-12-05       Impact factor: 4.430

4.  Clinically Relevant Response to Treatment with Olaparib in a Patient with Refractory Multidrug-Resistant Ovarian Cancer and Central Nervous System Involvement: A Case Report.

Authors:  Flavia Morales Vázquez; Horacio Noé López Basave; María Del Carmen Méndez Herrera; Ricardo Raziel Peña González
Journal:  Am J Case Rep       Date:  2020-11-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.